BioMarin Pharmaceutical Inc. Stock News

BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biomarin Pharma Earnings, Revenue Beat in Q4

BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q4 2021 Results - Earnings Call Transcript

BioMarin Pharmaceutical press release (BMRN): Q4 GAAP EPS of -$0.32 beats by $0.02.Revenue of $449.8M (-0.5% Y/Y) beats by $7.42M.For FY2022, the company expects revenue between…

- Full-year 2021 Total Revenues of $1.85 Billion; Revenues Excluding Kuvan Increased 11% Year-Over-Year

BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

BioMarin Pharmaceutical (NASDAQ:BMRN) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is -$0.01

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

It was a tough week for companies, patients and families hoping a gene therapy for the rare metabolic disease phenylketonuria is on its way. On Friday afternoon, after BioMarin had already announced its program would be on hold for at least several quarters, Homology Medicines disclosed that the FDA had

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

BioMarin stock tumbled Friday on a Food and Drug Administration setback for its experimental gene therapy in a rare disease.

BioMarin Pharmaceutical Inc (NASDAQ: BMRN ) said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN 307 issued in September 2021. BMN 307 is an AAV5-human phenylalanine hydroxylase (hPAH) gene therapy studied in adults with phenylketonuria (PKU). The … Full story available on Benzinga.com